Literature DB >> 27047301

Methylene Blue Is a Guanylate Cyclase Inhibitor That Does Not Interfere with Nitric Oxide Synthesis.

Paulo Roberto B Evora1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27047301      PMCID： PMC4810576          DOI： 10.14503/THIJ-15-5629

Source DB:  PubMed          Journal:  Tex Heart Inst J        ISSN： 0730-2347


× No keyword cloud information.
  5 in total

1.  Methylene Blue Is a Guanylate Cyclase Inhibitor That Does Not Interfere with Nitric Oxide Synthesis.

Authors:  Paulo Roberto B Evora
Journal:  Tex Heart Inst J       Date:  2016-02-01

Review 2.  Methylene blue for vasoplegic syndrome treatment in heart surgery: fifteen years of questions, answers, doubts and certainties.

Authors:  Paulo Roberto Barbosa Evora; Paulo José de Freitas Ribeiro; Walter Vilella de Andrade Vicente; Celso Luís dos Reis; Alfredo José Rodrigues; Antonio Carlos Menardi; Lafaiete Alves Junior; Patrícia Martinez Evora; Solange Bassetto
Journal:  Rev Bras Cir Cardiovasc       Date:  2009 Jul-Sep

3.  Inhibition of nitric oxide synthesis by methylene blue.

Authors:  B Mayer; F Brunner; K Schmidt
Journal:  Biochem Pharmacol       Date:  1993-01-26       Impact factor: 5.858

4.  A Reminder of Methylene Blue's Effectiveness in Treating Vasoplegic Syndrome after On-Pump Cardiac Surgery.

Authors:  Joshua Manghelli; Lisa Brown; Hany B Tadros; Nabil A Munfakh
Journal:  Tex Heart Inst J       Date:  2015-10-01

Review 5.  Twenty years of vasoplegic syndrome treatment in heart surgery. Methylene blue revised.

Authors:  Paulo Roberto Barbosa Evora; Lafaiete Alves Junior; Cesar Augusto Ferreira; Antônio Carlos Menardi; Solange Bassetto; Alfredo José Rodrigues; Adilson Scorzoni Filho; Walter Vilella de Andrade Vicente
Journal:  Rev Bras Cir Cardiovasc       Date:  2015 Jan-Mar
  5 in total
  6 in total

1.  Methylene Blue Is a Guanylate Cyclase Inhibitor That Does Not Interfere with Nitric Oxide Synthesis.

Authors:  Paulo Roberto B Evora
Journal:  Tex Heart Inst J       Date:  2016-02-01

2.  An ATR-FTIR Sensor Unraveling the Drug Intervention of Methylene Blue, Congo Red, and Berberine on Human Tau and Aβ.

Authors:  Jonas Schartner; Andreas Nabers; Brian Budde; Julia Lange; Nina Hoeck; Jens Wiltfang; Carsten Kötting; Klaus Gerwert
Journal:  ACS Med Chem Lett       Date:  2017-06-11       Impact factor: 4.345

Review 3.  Recent Advances in Pharmacological and Non-Pharmacological Strategies of Cardioprotection.

Authors:  Afonso Caricati-Neto; Paolo Ruggero Errante; Francisco Sandro Menezes-Rodrigues
Journal:  Int J Mol Sci       Date:  2019-08-16       Impact factor: 5.923

Review 4.  Ischemia/Reperfusion Injury Revisited: An Overview of the Latest Pharmacological Strategies.

Authors:  Ricardo O S Soares; Daniele M Losada; Maria C Jordani; Paulo Évora; Orlando Castro-E-Silva
Journal:  Int J Mol Sci       Date:  2019-10-11       Impact factor: 5.923

5.  Early Use of Methylene Blue in Vasoplegic Syndrome: A 10-Year Propensity Score-Matched Cohort Study.

Authors:  Othmar Kofler; Maximilian Simbeck; Roland Tomasi; Ludwig Christian Hinske; Laura Valentina Klotz; Florian Uhle; Frank Born; Maximilian Pichlmaier; Christian Hagl; Markus Alexander Weigand; Bernhard Zwißler; Vera von Dossow
Journal:  J Clin Med       Date:  2022-02-20       Impact factor: 4.241

Review 6.  The role of nitric oxide in brain disorders: Autism spectrum disorder and other psychiatric, neurological, and neurodegenerative disorders.

Authors:  Manish Kumar Tripathi; Maryam Kartawy; Haitham Amal
Journal:  Redox Biol       Date:  2020-05-15       Impact factor: 11.799
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.